Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Study Information
Alliance Study ID: NCCTG-N0849
NCT Study ID (ClinicalTrials.gov): NCT00938470
Alliance Committee: Gastrointestinal Cancer
Disease or Cancer Type: Gastrointestinal Cancers – Pancreatic / Gastric / Esophageal / Liver / Biliary
Alliance Study Chair: Steven R. Alberts, MD
Status: COMPLETED
Study Description
This randomized phase II trial studies how well docetaxel, oxaliplatin, capecitabine, fluorouracil, and radiation therapy works compared with fluorouracil when given together with oxaliplatin and radiation therapy in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as docetaxel, oxaliplatin, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information